Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-05-14

Clinical Trial Update: Efficacy of Dexmedetomidine in Preventing Contrast Induced Nephropathy [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update reports on the efficacy of dexmedetomidine in preventing contrast-induced nephropathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dexmedetomidine (Dexmedetomidine)

Snippet

Sponsor: TC Erciyes University | Conditions: Radiographic Contrast Agent Nephropathy | Phase 4 | Status: COMPLETED